Difference between revisions of "Tay-Sachs Disease 2011"

From Bioinformatikpedia
(Biochemical disease mechanism)
(Biochemical disease mechanism)
Line 38: Line 38:
   
   
  +
[[Image:hsa00604.png|frame|center|KEGG-Pathway Glycosphingolipid biosynthesis highlighting TSD associated enzyme Beta-Hexosaminidase A (http://www.genome.jp/tmp/mark_pathway130536834226114/hsa00604.png)]]
 
[[Image:hsa00604.png|frame|KEGG-Pathway Glycosphingolipid biosynthesis highlighting TSD associated enzyme Beta-Hexosaminidase A (http://www.genome.jp/tmp/mark_pathway130536834226114/hsa00604.png)]]
 
   
   

Revision as of 11:39, 14 May 2011

Summary

The Tay-Sachs disease (TSD) is a rare autosomal, recessive genetic disorder which is caused by accumulation of lipids in the brain. This leads to the cell death of those neurons. There exist three different variations of the TSD. The most common one is the Infantile Tay-Sachs disease which affects death of the children under the age of 5. The two other variants are the Juvenile and Adult/Late Onset TSD, which are less aggressive. The disease causes a deterioration of mental and physical abilities. Sadly, there currently exists no treatment.

Phenotype

Infantile Tay-Sachs disease:

The most common and aggressive form of TSD is the infantile TSD, which has a wide range of different symptoms and leads to the early death of the affected children. The most common symptoms are:

  • normal development in the first six month after birth
  • "cherry-red" macula
  • paralysis
  • dementia
  • blindness
  • deafness
  • muscle atrophy
  • startle response to sound stimuli
  • inability to coordinate muscle movement (child can't roll over and sit)
  • death in the second or third year


Juvenile and Adult TSD:

This forms of the Tay-Sachs disease occur later in lifetime. These two forms were not always recogniced as variants of the TSD. The symptomes of these forms are less aggressive. Often the patients become wheelchair users and have some psychiatric and physical limitation, which could be handled with drugs.


Cross-references

See also description of this disease in

Biochemical disease mechanism

The affecting protein in the TSD is the Beta-Hexosaminidase, which is a heterodimer consisting of two subunits alpha (encoded by the gene HEXA) and beta (encoded by the gene HEXB). The alpha subunit is responsible for the hydrolysis of the terminal N-hexosamines. Therefor the enzyme is responsible for the degradation of GM2 gangliosides (which are fatty acid derivatives) and other molecules in the brain and the tissue. In other words the enzyme breaks down the phospholipids. If the enzyme is defect it results in the accumulation of GM2 gangliosides in the neurons, which affect the death of those cells.


KEGG-Pathway Glycosphingolipid biosynthesis highlighting TSD associated enzyme Beta-Hexosaminidase A (http://www.genome.jp/tmp/mark_pathway130536834226114/hsa00604.png)



Cross-references

Mutations

Only mutations in the HEXA gene can results in the TSD, whereas mutations in the HEXB gene results in other metabolic diseases. Nowadays, there are more then 120 mutations known, which cause the TSD disease. These mutations suppress the activity of the Hexosamidase A. This has as an effect that the break down of the GM2 gangliosides doesn't work anymore, which leads to the toxic accumulation of these. There is a strong prevalence for the TSD in the Eastern European Jewish, Cajuns and French Canadians. Most of the mutations in HEXA lead to the TSD, because they delete the enzyme function completely, which cause the infantile form of TSD. There are other mutations, which only reduce the enzyme-activity and therefore, cause the Juvenile or Adult TSD.

Reference sequence

Neutral mutations

Disease causing mutations